Methylmercury Measurements in Dried Blood Spots from Electronic Waste Workers Sampled from Agbogbloshie, Ghana

Biomonitoring methylmercury (MeHg) exposure is problematic in resource-limited settings and with difficult-to-access populations where traditional biomarker approaches present logistical, economic, and ethical issues. The present study aimed to validate the use of dried blood spots (DBS) to assess MeHg exposure in a real-world contaminated field setting. Whole-blood and DBS samples were collected from electronic waste workers (n = 20) from Agbogbloshie (Ghana) in 2017, and DBS were also artificially created in the laboratory using the field-collected blood. Whole-blood MeHg concentrations averaged 0.84 µg/L, which was not different from levels measured in the corresponding DBS samples (field-collected or artificially created). Whole-blood MeHg comprised 61% of the blood total Hg concentrations. Linear regression analysis revealed no differences in MeHg concentrations between whole-blood samples and field-collected DBS (slope 0.89, R²  = 0.94) and between field and laboratory DBS (slope 0.89, R²  = 0.96). The MeHg content in DBS punch blanks averaged 0.86 pg and thus was not of concern. These findings indicate that DBS are a suitable tool for assessing MeHg exposure in real-world environmental settings that may be heavily contaminated.  Environ Toxicol Chem 2021;40:2183-2188. © 2021 SETAC.

Lead (Pb) exposure assessment in dried blood spots using Total Reflection X-Ray Fluorescence (TXRF)

Lead (Pb) exposure is often determined through the analysis of whole blood though venipuncture poses ethical, economic, and logistical barriers. Dried Blood Spots (DBS) may help overcome such barriers though past studies measuring Pb in DBS have been challenged with quality control, small sample volumes, and other issues. Total Reflection X-Ray Fluorescence (TXRF) may help address some of these challenges but has yet to be used to measure Pb in DBS. As such, the aim of the current study was to develop, validate, and apply a method to analyze Pb in DBS samples using TXRF for use in human biomonitoring studies. First, we developed a novel method (tested a range of parameters), and then used blood reference materials to validate the method against performance criteria listed in ICH Q2A and Q2B and the European Bioanalysis Forum. Finally, we applied the method to two populations who exemplify divergent conditions (41 university members with relatively low Pb exposures sampled in a clinical environment; 40 electronic waste workers with relatively high Pb exposures sampled in a contaminated field setting). The limits of detection and quantification of the method were 0.28 and 0.69 μg/dL, respectively. The overall precision and accuracy of the method were 15% and 111%, respectively. The mean (±SD) DBS Pb levels by TXRF in the university members and e-waste workers were 0.78 (±0.46) and 3.78 (±3.01) μg/dL, respectively, and these were not different from Pb measures in venous whole blood using ICP-MS. Bland-Altman plot analyses indicated good agreement between DBS Pb measures by TXRF versus whole blood Pb measures by ICP-MS in both groups. By combining data from the two population groups, there was no significant constant bias (intercept of 0.02 μg/dL) or proportional bias (slope was -0.02) between the two measures, and the lower and upper LoA were -0.86 and 0.91 μg/dL, respectively, with a LoA range of 1.77 μg/dL. These results demonstrate that TXRF-based analysis of Pb content in DBS is a good alternative to the gold standard (i.e., ICP-MS analysis of whole blood), and helps overcome some of the challenges associated with current methods.